Terbinafine for Dogs: An Alternative Antifungal for Resistant Infections

Based on peer reviewed veterinary research · For educational purposes only · Updated October 2026 · 9 min read

What Is Terbinafine and How Does It Work in Dogs?

Terbinafine is an oral allylamine antifungal drug used in dogs to treat dermatophytosis (ringworm) and Malassezia dermatitis (yeast overgrowth), particularly when azole antifungals have failed or cannot be used. It is prescribed off label in veterinary medicine, but it is one of the best studied systemic antifungals in companion animal dermatology.

Terbinafine works by inhibiting squalene epoxidase, an enzyme fungi require early in the ergosterol synthesis pathway. Ergosterol is the structural sterol of the fungal cell membrane, roughly equivalent to cholesterol in animal cells. Blocking squalene epoxidase does two things at once: it starves the membrane of ergosterol, and it causes toxic squalene to accumulate inside the fungal cell. That second effect is why terbinafine is fungicidal against dermatophytes rather than fungistatic, meaning it kills the organism instead of simply halting its replication.

Azole antifungals such as ketoconazole and itraconazole act further down the same pathway, inhibiting lanosterol 14 alpha demethylase. Because terbinafine and the azoles hit different enzymes, an organism that tolerates one class does not automatically tolerate the other. That difference in target is the entire clinical rationale for reaching for terbinafine when an azole has underperformed.

Terbinafine is also highly lipophilic and keratinophilic. After absorption it concentrates in sebum, stratum corneum, and hair shafts, which is exactly where dermatophytes live. Sakai and colleagues (2011) showed that after a single oral dose in dogs, drug concentrations in hair remained measurable for weeks, far outlasting plasma levels.

What Causes Antifungal Treatment Failure in Dogs?

Most apparent antifungal resistance in dogs is not true drug resistance. It is a failure of exposure, duration, or diagnosis. Understanding which of the three is in play changes the treatment plan far more than switching molecules does.

Inadequate absorption is the most common culprit with azoles. Ketoconazole and itraconazole depend on gastric acidity and dietary fat for absorption. A dog dosed on an empty stomach, or one receiving antacids or proton pump inhibitors, may absorb a fraction of the intended dose. Terbinafine absorption is far less dependent on gastric pH, which alone can explain why it succeeds where an azole did not.

Premature discontinuation is the second. Dermatophytosis looks resolved long before it is cured. The World Association for Veterinary Dermatology consensus guidelines recommend continuing systemic therapy until two consecutive negative fungal cultures are obtained, not until the coat looks normal. Owners who stop at visible improvement frequently see relapse within weeks.

Misdiagnosis is the third and most consequential. Demodicosis, pemphigus foliaceus, epitheliotropic lymphoma, and sebaceous adenitis can all produce scaling and alopecia that mimics fungal disease. If cytology, culture, or dermatophyte PCR was never performed, an antifungal was never going to work. A structured symptom review, such as the Dog Skin Condition Checker, helps owners frame the right questions before the appointment.

True resistance does exist. Terbinafine resistant Trichophyton strains carrying squalene epoxidase point mutations are a growing concern in human dermatology and have been reported in animals, but they remain uncommon in routine small animal practice.

How Do Veterinarians Choose Between Terbinafine and Azole Antifungals?

The choice is driven by the organism, the patient's liver and drug history, and whether a fungicidal or fungistatic effect is needed. For confirmed dermatophytosis, itraconazole and terbinafine are both first line in the 2017 consensus guidelines. For Malassezia dermatitis, azoles have the longer track record, though terbinafine performed comparably in a controlled comparison by Rosales and colleagues (2005).

Terbinafine Dosing, Duration, and Monitoring

The dose used in dogs is considerably higher than the human dose on a per kilogram basis, which surprises many owners. Consensus guidance from the World Association for Veterinary Dermatology is 30 to 40 mg/kg orally once daily for dermatophytosis. Doses at the lower end of that range, or the 10 to 20 mg/kg figures occasionally quoted from older sources, are associated with treatment failure.

Terbinafine is given with food to improve tolerance, and the tablet does not need to be given with fat in the way itraconazole capsules do. Duration is dictated by mycological cure, not cosmetic improvement. For dermatophytosis, that means treating until two consecutive fungal cultures taken roughly two weeks apart are negative, which commonly takes six to ten weeks and can take longer in long coated breeds or multi pet households.

Pulse protocols exploit the drug's persistence in keratin. Berger and colleagues (2012) ran a pilot comparison of once daily versus twice weekly terbinafine for canine Malassezia dermatitis and found comparable clinical control, with substantially lower total drug exposure. Pulse dosing is not a substitute for adequate initial therapy, but it is a reasonable maintenance strategy in dogs with a documented tendency to relapse.

Monitoring is straightforward. A baseline serum biochemistry panel is standard, with a recheck after two to four weeks of therapy. Vomiting and inappetence are the most common adverse effects and are usually mild. Idiosyncratic hepatotoxicity is rare but real, and any dog that becomes jaundiced, lethargic, or anorexic on therapy should be reassessed promptly. Facial pruritus has been reported in cats receiving terbinafine and typically resolves on discontinuation.

Treatment Options: Pairing Systemic and Topical Therapy

Systemic antifungal therapy alone is rarely the whole plan. Dermatophyte spores sit on the hair coat and in the environment, and a dog with a sterilised hair follicle can be reinfected from its own bedding within days. This is why every major consensus guideline pairs oral therapy with topical therapy for the duration of treatment.

Topical therapy does two jobs. It reduces the infectious spore load the dog sheds into the household, and it lowers the surface population of secondary organisms, particularly Malassezia pachydermatis and Staphylococcus pseudintermedius, which colonise inflamed and self traumatised skin. Mueller and colleagues (2012) reviewed topical antimicrobial therapy in dogs and concluded that twice weekly medicated bathing meaningfully reduces surface organism counts and supports systemic treatment.

Chlorhexidine Shampoo contains chlorhexidine gluconateand ketoconazole, a pairing chosen for exactly this adjunct role. Chlorhexidine is a cationic biguanide that disrupts the bacterial cell membrane and precipitates cytoplasmic contents, and ketoconazole acts on the same ergosterol pathway described earlier, from the outside of the skin rather than through the bloodstream. Used alongside a prescribed oral antifungal, that combination addresses the surface burden the tablet reaches slowly. It is an FDA registered over the counter veterinary drug listed on DailyMed, not a cosmetic shampoo, and the distinction matters when a clinician is building a protocol.

Contact time is the variable owners most often get wrong. A medicated shampoo needs roughly ten minutes on the coat before rinsing. Anything shorter is a wash, not a treatment. For background on the surface organisms involved, see The Fungal Microbiome of Dog Skin and the condition overview at Ringworm in Dogs.

Signs and Symptoms to Watch During Treatment

Response to terbinafine is gradual, and the visual timeline confuses owners because the drug works on the follicle before it works on the coat. Hair that is already damaged does not repair itself; it has to grow out. Expect the lesion margin to stop advancing within two to three weeks, scaling and crusting to settle over three to five weeks, and visible regrowth to lag behind both.

Encouraging signs include a sharply defined, non expanding lesion edge, resolution of erythema at the periphery, reduced scaling, absence of new lesions elsewhere on the body, and a falling fluorescence score in Microsporum canis cases assessed under a Wood's lamp. Fine downy regrowth inside the lesion is a strong positive indicator.

Concerning signs fall into two categories. Treatment failure signs include new satellite lesions after three weeks of therapy, continued expansion of existing lesions, and persistently positive cultures past week eight. Drug intolerance signs include repeated vomiting, sustained appetite loss, yellow tinged gums or sclera, and unusual lethargy.

Secondary bacterial infection frequently complicates the picture. Pustules, epidermal collarettes, yellow crusting, and a distinct odour suggest pyoderma layered on top of the fungal disease, and that requires its own assessment rather than a longer antifungal course. Cytology distinguishes the two in minutes, which is why skin impression smears remain such a high value in clinic test.

Prevention and Long-Term Management

Preventing recurrence is mostly about the environment and the underlying patient, not about the drug. Dermatophyte spores remain viable in the environment for months, and reinfection from an untreated reservoir is the single most common reason a cured dog relapses.

Environmental decontamination means mechanical removal first and disinfection second. Vacuuming and laundering do most of the work; washing textiles on the longest cycle available is more effective than adding any particular product. Hard surfaces can be disinfected with an accelerated hydrogen peroxide or appropriately diluted sodium hypochlorite product, applied to a surface that is already physically clean. In multi pet households, every in contact animal should be cultured, because asymptomatic carriers sustain an outbreak indefinitely.

The second half of prevention is the patient. Recurrent fungal or yeast overgrowth in an adult dog is frequently secondary to something else: atopic dermatitis, endocrinopathy, or immunosuppressive therapy. A dog whose Malassezia dermatitis returns within weeks of stopping treatment does not primarily have a yeast problem. It has a barrier or immune problem that yeast is exploiting, and treating only the yeast guarantees a repeating cycle.

Long term, the practical maintenance package is routine medicated bathing at an interval set by the clinician, prompt drying of skin folds and feet, periodic cytology in dogs with a relapsing history, and control of the underlying allergic or endocrine driver. Dogs managed this way generally need systemic antifungals far less often, which is the real goal, since every course of oral therapy carries a small hepatic risk that topical maintenance does not.

Frequently Asked Questions

How long does terbinafine take to work in dogs?

Lesion margins usually stop expanding within two to three weeks, with scaling and crusting settling by weeks three to five. Visible hair regrowth lags behind because damaged hair must grow out rather than repair. Mycological cure, confirmed by two consecutive negative fungal cultures, commonly takes six to ten weeks.

What is the correct terbinafine dose for a dog?

Consensus guidance from the World Association for Veterinary Dermatology is 30 to 40 mg/kg orally once daily for dermatophytosis, given with food. This is substantially higher per kilogram than the human dose. The exact dose must come from your veterinarian, who will match it to your dog's weight, liver status, and other medications.

Is terbinafine better than ketoconazole for dogs?

Neither is universally better. Terbinafine is fungicidal against dermatophytes and its absorption does not depend on stomach acid, which is an advantage in dogs on antacids. Ketoconazole has a longer track record for Malassezia dermatitis but inhibits adrenal steroid synthesis and interacts strongly with cytochrome P450 3A substrates such as cyclosporine.

Can terbinafine damage a dog's liver?

Idiosyncratic hepatotoxicity is a recognised but uncommon adverse effect. Standard practice is a baseline serum biochemistry panel with a recheck after two to four weeks of therapy. Jaundice, sustained appetite loss, or unusual lethargy during treatment warrants prompt reassessment and discontinuation pending results.

Sources

1. Moriello KA, Coyner K, Paterson S, Mignon B. Diagnosis and treatment of dermatophytosis in dogs and cats: Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. Veterinary Dermatology. 2017;28(3):266-e68.
2. Sakai MR, May ER, Imerman PM, et al. Terbinafine pharmacokinetics after single dose oral administration in the dog. Veterinary Dermatology. 2011;22(6):528-534.
3. Rosales MS, Marsella R, Kunkle G, et al. Comparison of the clinical efficacy of oral terbinafine and ketoconazole combined with cephalexin in the treatment of Malassezia dermatitis in dogs. Veterinary Dermatology. 2005;16(3):171-176.
4. Berger DJ, Lewis TP, Schick AE, Stone RT. Comparison of once daily versus twice weekly terbinafine administration for the treatment of canine Malassezia dermatitis, a pilot study. Veterinary Dermatology. 2012;23(5):418-e79.
5. Mueller RS, Bergvall K, Bensignor E, Bond R. A review of topical therapy for skin infections with bacteria and yeast. Veterinary Dermatology. 2012;23(4):330-e62.
6. Kotnik T, Kozuh Erzen N, Kuzner J, Drobnic-Kosorok M. Terbinafine hydrochloride treatment of Microsporum canis experimentally induced ringworm in cats. Veterinary Microbiology. 2001;83(2):161-168.

Related Reading

• Fluconazole vs Ketoconazole for Dogs: Choosing the Right Antifungal
• The Fungal Microbiome (Mycobiome) of Dog Skin: Beyond Bacteria
• Skin Impression Smears in Dogs: A Quick Diagnostic Tool for Infections

E. Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.

Research basis: All Vetified content references peer reviewed research published in journals including Veterinary Dermatology, JAVMA, and Journal of Small Animal Practice.